louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05168956: Characteristics of Genealogical Representations of Perpetrators of Sexual Violence.
Official title: Apparent Characteristics of Genealogical Representations of Perpetrators of Sexual Violence.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sexual Offence
Keywords: Sexual abuse
family
sexual offenders
incest
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
First posted: 2021-12-23
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients followed up in the sexual offender's department of University Hospital of Saint Etienne will be included.

Brief summary: Two French studies report that 25% of sexual abuse occurs in intrafamily sphere. To be victim of sexual abuse leads to cognitive troubles and redesign of psychological processes. Lot of studies report that offenders had been victims (30-97%). How psychological redesign is destroying genealogical representation and hinders the proper construction of family ties.

This study to study characteristics data about family, and how the patients see it, from medical records of a specific department for sexual offenders in University Hospital of Saint Etienne. Study is realized blind from criminal categories. Data are gathered with a standardized grid, to guarantee reproducibility of data collection.

Detailed description: The CARG-AVS study does not involve any additional examinations or consultations compared to usual practice. It consists of collecting information from patients' medical records.

Eligibility criteria: Inclusion Criteria:

* Patients followed up in the sexual offender's department of University Hospital of Saint Etienne.
* Patients who did the nursing assessment at time of analysis.

Exclusion Criteria:

* Patients in the preliminary follow up in the department
* Refusal to participate at this study

Primary outcomes:
measure: Characteristic of family
timeFrame: the day of the medical file review
Secondary outcomes:
measure: Family members
timeFrame: the day of the medical file review
measure: Incestuous relationships
timeFrame: the day of the medical file review
measure: Psychological traumatisms: sexual abuse
timeFrame: the day of the medical file review
measure: Psychological traumatisms: brutal deat
timeFrame: the day of the medical file review
measure: Psychological traumatisms: severe illness
timeFrame: the day of the medical file review
measure: Psychological traumatisms: suicide
timeFrame: the day of the medical file review
measure: Criminal category
timeFrame: the day of the medical file review
Other outcomes:
Locations:
city: Saint-Étienne
country: France
facility: CHU Saint-Etienne
Study officials:
affiliation: CHU SAINT-ETIENNE
name: Tristan GABRIEL, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01227356: A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia
Official title: A Randomized Study Comparing Imatinib And Imatinib/Pegylated Interferon Alpha-2B in Newly Diagnosed Non-high Risk Chronic Myeloid Leukemia Patients in Complete Hematological Remission After Imatinib Induction Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Health Care Quality
Health Care Evaluation
Keywords: Chronic myeloid leukemia, imatinib, interferon
Lead sponsor: Uppsala University
Sponsor class: OTHER
Collaborators: name: Uppsala University Hospital
name: Karolinska University Hospital
First posted: 2010-10-25
Enrollment: 112
Sex: ALL
Minimum age (years): 18
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with chronic myeloid leukemia in imatinib induced CHR are randomized between imatinib 400 mg daily and imatinib 400 mg daily + PegIntron 30 ug weekly.

Primary endpoint: To compare at 12 months between the treatment arms the rate of Major Molecular Response (=99,9% tumour reduction) at 12 months

Detailed description: 130 patients registered, 112 randomized. 56 pats in each treatment arm. 12 months study duration. Rate of Major Molecular Response was at 12 months 53 vs 82 % (p=0.002) in favour of the combination arm.

Eligibility criteria: Inclusion Criteria:

Chronic myeloid leukemia in imatinib induced complete hematological remission. Intermediate/low risk, ECOG \< 2

Exclusion Criteria:

Les than CHR after 3 months imatinib high risk More than 6 months from diagnosis ECOG \> 2 Pregnancy

-

Primary outcomes:
measure: Comparison of rate Major Molecular Response between treatment arms
timeFrame: 2004 - 2009
Secondary outcomes:
measure: Comparison of complete cytogenetic response between the treatment arms at 12 months
timeFrame: 2004 - 2009
measure: Comparison rate complete cytogenetic response between the treatment arms at 12 months
timeFrame: 2004 - 2009
Other outcomes:
Locations:
city: Uppsala
country: Sweden
facility: Bengt Simonsson
city: Uppsala
country: Sweden
facility: Uppsala University Hospital
city: Uppsala
country: Sweden
facility: Uppsala University Hospital
Study officials:
affiliation: Uppsala University
name: bengt NO Simonsson, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT05387356: Evaluation of the Efficiency and Complications of the Consequtive Proning in Covid -19 ICU
Official title: Evaluation of the Efficiency and Complications of the Consequtive Proning in Covid -19 ICU: A Retrospective Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Respiratory Distress Syndrome
COVID-19 Respiratory Infection
Keywords: prone position
intensive care unit
Lead sponsor: Kecioren Education and Training Hospital
Sponsor class: OTHER
First posted: 2022-05-24
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Intensive care patient population who were intubated a positive test result for SARS-CoV-2 RNA through nasopharyngeal swab and underwent three subsequent prone positions for 16 hours will be enrolled the study. -

Brief summary: Thirty -one confirmed Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2 ) infected patients with Acute Respiratory Distress Syndrome (ARDS) and placed in prone position(PP) for 3 times (PP1, PP2, PP3)consecutively will be included. Arterial blood gases (ABG), partial pressure of arterial oxygen/ fraction of inspired oxygen (PaO2/FiO2 ) ratios, partial pressure of carbondioxide (PaCO2), positive end expiratory pressure (PEEP), and fraction of inspired oxygen (FiO2) values will be recorded before (bPP), during (dPP)and after (aPP) every prone positioning. Eye, skin, nerve and tube complications related to prone positions wll be recorded


Eligibility criteria: Inclusion Criteria:

a positive test result for SARS-CoV-2 RNA through nasopharyngeal swab and underwent three subsequent prone positions for 16 hours will be enrolled the study. -

Exclusion Criteria:

negative test result for SARS-CoV-2 RNA -

Primary outcomes:
measure: effects of prone position
timeFrame: 15 days
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Health Sciences University
Study officials:
References:
Clinical trial NCT06853756: Gastric Insufflation Volume Using I-gel Versus Ambu AuraGain in Pediatric Patients Undergoing Elective Orthopedic Operations Under General Anesthesia
Official title: Gastric Insufflation Volume Using I-gel Versus Ambu AuraGain in Pediatric Patients Undergoing Elective Orthopedic Operations Under General Anesthesia: a Prospective Randomized Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Gastric Insufflation
I-gel
Ambu AuraGain
Pediatric
Orthopedic Operations
General Anesthesia
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2025-03-03
Enrollment: 60
Sex: ALL
Minimum age (years): 2
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Our study aimed to compare the gastric insufflation volume between Ambu AuraGain and i-gel and its relationship with the oropharyngeal sealing pressure and the incidence of postoperative complications in generally anesthetized controlled-ventilated pediatric patients undergoing elective orthopedic operations.

Detailed description: Supraglottic Airway Devices (SADs) refer to a wide range of medical devices that can act as a passageway for oxygenation, ventilation, and administration of anesthetic gases and may be deemed an alternative to Endotracheal Tubes (ETTs).

Oropharyngeal sealing pressure (OLP) provides insight into the risk of gastric insufflation and aspiration risk. It is considered a measure of adequate performance and successful placement based on the premise that the SAD is sited properly in the hypopharynx after blind placements, and it is a useful comparator between SADs.

Eligibility criteria: Inclusion Criteria:

* Aged from 2 to 12 years.
* Both sexes.
* American Society of Anesthesiologists (ASA) physical status I and II.
* Scheduled for elective orthopedic operations in a supine position under general anesthesia.

Exclusion Criteria:

* Patients with a known history of gastro-oesophageal reflux disorders.
* Full Stomach.
* Anticipated difficult mask ventilation or intubation.
* Body mass index "BMI" exceeding 20% of the ideal.
* A history of chest problems.
* History of the gastrointestinal tract or thoracic surgeries.

Primary outcomes:
measure: Gastric antrum cross-sectional area (CSA)
timeFrame: At the end of surgery before supraglottic airway devices removal (5 min)
Secondary outcomes:
measure: Oropharyngeal leak pressure
timeFrame: Intraoperatively
measure: Time of insertion of supraglottic airway devices
timeFrame: Intraoperatively
measure: Number of attempts for insertion
timeFrame: Intraoperatively
measure: Incidence of postoperative complications
timeFrame: 24 hours postoperatively
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University
state: El-Gharbia
Study officials:
References:
Clinical trial NCT06836856: Evaluating the Impact of Adjuvant Use of Beta Blockers on Clinical Outcomes in Patients With Traumatic Brain Injury
Official title: Evaluating the Impact of Adjuvant Use of Beta Blockers on Clinical Outcomes in Patients With Traumatic Brain Injury
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: TBI Traumatic Brain Injury
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2025-02-20
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Propranolol primarily acts as a non-selective beta blocker, blocking both beta-1 and beta-2 adrenergic receptors, while carvedilol exhibits a broader spectrum of action by also blocking alpha-1 adrenergic receptors. The receptor blockade profile of a beta blocker can influence its physiological effects and potential therapeutic benefits in TBI. Therefore, the variation in receptor selectivity may result in differences in their impact on secondary brain injury processes and patient outcomes.


Eligibility criteria: Inclusion Criteria:

1. Patients with moderate \& severe TBI detected on admission by CT scan and GCS score of ≤ 13 who either do not have any other injuries or only have associated minor injuries.

Minor injuries are defined as presence of any of the following:

1. Mild intraperitoneal free fluid (IPFF) observed through abdominal ultrasound.
2. mild lung contusion detected in the chest CT scan.
3. hemothorax or pneumothorax present without accompanying symptoms of hypoxia, tachypnea, or respiratory distress.
4. simple limb fractures.

Exclusion Criteria:

1. Patients on pre-injury beta-blocker therapy.
2. Patients with any bronchospastic conditions.
3. Patients with active acute coronary syndrome.
4. TBI with GCS ≤ 13 with associated major injuries defined as the presence of any of the following:

   1. Moderate \& marked IPFF requiring surgical intervention ( laparotomy ).
   2. moderate \& marked lung contusion, pneumothorax \& hemothorax with accompanying symptoms of hypoxia, tachypnea, lower limbs, or limb amputation.
   3. Compound fracture in the upper or lower limb.
   4. Open Faciomaxillary trauma.
5. Patients with persistent shock (systemic blood pressure \<100 mmHg, base deficit \> 4, or oliguria , HR \< 60 b/min ) after \> one week of admission.

Primary outcomes:
measure: Incidence of In-hospital mortality
timeFrame: 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Zagazig
country: Egypt
facility: Zagazig University Hospitals, Zagazig,
city: Zagazig
country: Egypt
facility: Zagazig University Hospitals
Study officials:
References:
Clinical trial NCT02098356: Comparison of High Versus Low Bicarbonate Hemodialysis
Official title: Intradialytic Acid-base Changes and Organic Anion Production With High Versus Low Bicarbonate Hemodialysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Kidney Disease
End-stage Renal Disease
Metabolic Acidosis
Keywords: hemodialysis
dialysis
acidosis
bicarbonate
Lead sponsor: Albert Einstein College of Medicine
Sponsor class: OTHER
First posted: 2014-03-28
Enrollment: 7
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will compare hemodialysis treatment with a standard, high-bicarbonate dialysis bath versus a lower bicarbonate dialysis bath, and will compare intradialytic acid-base changes and overall control of metabolic acidosis with the 2 treatment regimens.

Detailed description: This study will compare hemodialysis treatment with a standard, high-bicarbonate dialysis bath versus a lower bicarbonate dialysis bath, and will compare intradialytic acid-base changes and overall control of metabolic acidosis with the 2 treatment regimens. These parameters will be assessed in patients currently receiving high-bicarbonate hemodialysis as part of usual care. They will then be switched to a lower bicarbonate prescription, after which these parameters will be reassessed. The study will also examine changes in inflammatory markers, glycemic control, ketogenesis, and lipolysis.

Eligibility criteria: Inclusion Criteria:

* Age \>18
* Receiving chronic thrice-weekly conventional hemodialysis for at least 6 months

Exclusion Criteria:

* Use of oral alkali within the previous month
* Hospitalization within the previous month
* Inability to provide written informed consent
* Plans for kidney transplant in the next 2 months
* Planned change in phosphate binder therapy within the next month
* Pregnancy, or planned pregnancy in the next 2 months

Primary outcomes:
measure: Pre-dialysis serum bicarbonate
timeFrame: 5 weeks
Secondary outcomes:
measure: serum beta-hydroxybutyrate
timeFrame: 5 weeks
measure: beta-hydroxybutyrate clearance
timeFrame: 5 weeks
measure: interleukin-6
timeFrame: 5 weeks
measure: serum free fatty acids
timeFrame: 5 weeks
measure: Time to recover from dialysis
timeFrame: 5 weeks
measure: Dialysis symptom questionnaire
timeFrame: 5 weeks
Other outcomes:
Locations:
city: Bronx
country: United States
facility: Albert Einstein College of Medicine
state: New York
Study officials:
affiliation: Albert Einstein College of Medicine
name: Matthew Abramowitz, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01493856: A Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276
Official title: A Randomized, Open Label, Single-Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276 in Healthy Male Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Lead sponsor: Daewoong Pharmaceutical Co. LTD.
Sponsor class: INDUSTRY
First posted: 2011-12-16
Enrollment: 58
Sex: MALE
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The purpose of this study is to evaluate the safety and pharmacokinetic characteristics of combination of rosuvastatin and CS-866 and DWJ1276 alone.


Eligibility criteria: Inclusion Criteria:

1. Healthy adult male volunteers aged 20 to 50 years
2. A subject who provided written informed consent to participate in this study and cooperative with regard to compliance with study related constraints

Exclusion Criteria:

1. A subject who had any allergic history to any drug.
2. A subject with sign or symptoms or previously diagnosed disease of liver, kidney, neurology, respiratory, endocrinology, hematology, cardiovascular, genitourinary, psychology, ophthalmic, dermatology and gastrointestinal function or other significant diseases
3. History or suspicion of current drug abuse
4. A subject who had received treatment with below listed drug within specified period prior to the first dose of study medication

   * Within 1 month: drug known CYP inducer or inhibitor
   * Within 2 weeks: Prescribed or herbal medicine
   * Within 1 weeks: OTC medicine
   * Within 2 days: Consumption of caffeine
5. A subject who had participated in any other clinical study within the last 2 weeks
6. A subject from whom over 400mL of blood was sampled(whole blood donation) within last 2 weeks or plasma/platelet donation within 1 month.

Primary outcomes:
measure: AUClast
timeFrame: 18 time points up to 72 hours
measure: Cmax
timeFrame: 18 time points up to 72 hours
Secondary outcomes:
measure: AUCinf
timeFrame: 18 time points up to 72 hours
measure: T1/2
timeFrame: 18 time points up to 72 hours
measure: %AUCextra
timeFrame: 18 time points up to 72 hours
measure: Tmax
timeFrame: 18 time points up to 72 hours
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Yonsei University Health System (Yuhs)
Study officials:
affiliation: YONSEI UNIVERSITY HEALTH SYSTEM (YUHS)
name: Kyungsoo Park, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03177356: Implant Placement in Mandibular Molar Xenograft Versus PRF
Official title: Immediate Implant Placement With Deproteinized Bovine Bone (Tutogen) Versus Placement of Platelet-rich Fibrin as a Space Filling Material in Mandibular Molars. Randomized Clinical Trial.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Edentulous Alveolar Ridge
Keywords: Platelet rich fibrin,xenograft
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2017-06-06
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 20 recruited patients indicated for immediate implant placement in mandibular molar patients are divided into 2 groups each group contain 15 patients, one group assigned for placement of bovine bone after molar extraction and immediate implant placement, while the other group we use Platelet-rich fibrin as space filling material.


Eligibility criteria: Inclusion Criteria:

1. Patients with non-restorable mandibular molars
2. Both sexes

   -

   Exclusion Criteria:
   * • Heavy smokers more than 20 cigarettes per day.5

     * Patients with in sufficient interseptal bone height and width

       * Patients with systemic disease that may affect normal healing.
       * Patients with completely resorbed buccal cortical plate.

Primary outcomes:
measure: Patient satisfaction
timeFrame: 1 week post operative
Secondary outcomes:
measure: implant stability
timeFrame: will be measure intraopertively immediately after insertion of the implants and will be measure one more time 6 months after 1st operation at the time of exposure of implants
measure: amount of bone gained or lost around the implants
timeFrame: 6 months postoperative
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01595256: Exploration the Effect of Walking Program in Patients With Colorectal Cancer
Official title: Exploration the Effect of Individualized Home-based Walking Program on Muscle Strength and Fatigue in Patients With Colorectal Cancer Both During and After Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colorectal Cancer
Keywords: colorectal cancer,fatigue,6-minute walking test
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
Collaborators: name: National Science and Technology Council, Taiwan
First posted: 2012-05-10
Enrollment: 237
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The aims of this four-year study are to

1. explore the relationships between fatigue and muscle strength (i.e., upper limbs and lower legs)
2. comparison with the effects of 8-week, 12-week moderate intensity of walking program on muscle strength and fatigue.
3. develop a clinical guidelines of home-based walking program for patients with colorectal cancer receiving active treatment and survivors in Taiwan.
4. explore the relationships among the self-report fatigue intensity and metabolism.


Eligibility criteria: Inclusion Criteria:

* Patients with colorectal cancer in receiving active treatment or completed treatment within 5years.
* Patients in Different Stages.
* Aged above 18.

Exclusion Criteria:

* KPS\<60

Primary outcomes:
measure: Exploration the Effect of Walking Program in Patients With Colorectal Cancer.
timeFrame: five-year study
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University
name: Shiow-Ching Shun, PhD
role: PRINCIPAL_INVESTIGATOR
References: